A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir | Zendy

Wang Y. | Zendy; Liu P. | Zendy

Premium

A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir

Author(s) -

Wang Y.,

Liu P.

Publication year - 2017

Publication title -

journal of clinical pharmacy and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.622

H-Index - 73

eISSN - 1365-2710

pISSN - 0269-4727

DOI - 10.1111/jcpt.12467

Subject(s) - dermatology , sofosbuvir , drug eruption , medicine , psoriasis , erythema multiforme , drug , pharmacology , virology , hepatitis c virus , virus , ribavirin

Summary What is known and the objective Sofosbuvir ( SOF ) and daclatasvir ( DCV ) have revolutionized the treatment of hepatitis C virus and now represent the preferred therapy for this disease. Limited data are available on the dermatological side effects resulting from co‐administration of SOF and DCV . Case description We report a case of an erythema multiforme drug eruption associated with erythrodermic psoriasis induced by SOF and DCV . After ceasing treatment, the skin condition significantly improved. What is new and conclusion We should pay attention to adverse skin reactions resulting from SOF and DCV , especially if the patient has a pre‐existing dermatosis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research